Comments
Sun Pharma Advanced Research Compan y on Tuesday announced the grant of an exclusive licence to Tripoint Therapeutics LLC, USA to commercialise the Elepsia XR tablets.
Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for Elepsia tablets.
The initial term of the agreement shall be five years and may be further extended as per mutual understanding between the parties.
The shares gained as much as 3.4 per cent to ₹174.65.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.